Steven M Belknap

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4153439/publications.pdf

Version: 2024-02-01

58 papers 2,556 citations

331670 21 h-index 233421 45 g-index

58 all docs 58 docs citations

58 times ranked 2540 citing authors

#	Article	IF	Citations
1	Current vs past use of NSAIDs was linked to increased risk for first HF hospitalization; risk varied by drug. Annals of Internal Medicine, 2017, 166, JC23.	3.9	О
2	Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis. Pediatric Dermatology, 2017, 34, 433-437.	0.9	23
3	Persistent erectile dysfunction in men exposed to the $5\hat{l}_{\pm}$ -reductase inhibitors, finasteride, or dutasteride. PeerJ, 2017, 5, e3020.	2.0	59
4	Hypomagnesemia and exposure to romidepsin: A Research on Adverse Drug events and Reports (RADAR) project Journal of Clinical Oncology, 2017, 35, e14072-e14072.	1.6	0
5	POP-PL: a patient-oriented prescription programming language. ACM SIGPLAN Notices, 2016, 51, 131-140.	0.2	3
6	Review: Statins do not increase adverse cognitive effects in patients with or without initial cognitive impairment. Annals of Internal Medicine, 2015, 162, JC6.	3.9	0
7	Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project. Drug Safety, 2015, 38, 183-187.	3.2	52
8	Disclosure of Boxed Warnings to Research Participants. JAMA Internal Medicine, 2015, 175, 1567.	5.1	0
9	Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia. JAMA Dermatology, 2015, 151, 600.	4.1	53
10	POP-PL: a patient-oriented prescription programming language. , 2015, , .		3
11	Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology, 2014, 44, 173-180.	2.0	74
12	In adults, use of anxiolytic or hypnotic drugs was associated with increased risk for mortality. Annals of Internal Medicine, 2014, 161, JC11.	3.9	2
13	Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration's Adverse Event Reporting System Narratives. JMIR Medical Informatics, 2014, 2, e10.	2.6	28
14	Results from the First Decade of Research Conducted by the Research on Adverse Drug Events and Reports (RADAR) Project. Drug Safety, 2013, 36, 335-347.	3.2	15
15	Automatic detection of drug interaction mismatches in package inserts. , 2013, , .		O
16	Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. Seminars in Thrombosis and Hemostasis, 2013, 39, 112-112.	2.7	2
17	Bisphosphonates and Nonhealing Femoral Fractures: Analysis of the FDA Adverse Event Reporting System (FAERS) and International Safety Efforts. Journal of Bone and Joint Surgery - Series A, 2013, 95, 297-307.	3.0	100
18	Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. Expert Opinion on Drug Safety, 2013, 12, 299-307.	2.4	9

#	Article	IF	CITATIONS
19	Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project. Journal of Oncology Practice, 2013, 9, 101-106.	2.5	18
20	NSAIDs were associated with increased risk for mortality, regardless of time since first MI. Annals of Internal Medicine, 2013, 158, JC10.	3.9	0
21	Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. Seminars in Thrombosis and Hemostasis, 2012, 38, 893-904.	2.7	53
22	Amiodarone-associated Optic Neuropathy: A Critical Review. American Journal of Medicine, 2012, 125, 447-453.	1.5	64
23	Comparison of the Sensitivity of a Pre-MRI Questionnaire and Point of Care eGFR Testing for Detection of Impaired Renal Function. Academic Radiology, 2012, 19, 1181-1185.	2.5	9
24	Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project. Blood, 2012, 120, 1351-1351.	1.4	1
25	Novel risk factors for osteonecrosis of the jaw in multiple myeloma: A RADAR report Journal of Clinical Oncology, 2012, 30, 6623-6623.	1.6	O
26	Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report Journal of Clinical Oncology, 2012, 30, 2532-2532.	1.6	0
27	Bisphosphonates and esophageal cancer: A RADAR report Journal of Clinical Oncology, 2012, 30, 4063-4063.	1.6	0
28	Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive. Blood, 2012, 120, 4692-4692.	1.4	1
29	Review: Rapid-response teams do not reduce mortality in hospital patients. Annals of Internal Medicine, 2010, 152, JC6.	3.9	1
30	Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate. Clinical Cancer Research, 2009, 15, 3850-3855.	7.0	25
31	A ward-based pharmacist intervention reduced emergency department visits and drug-related readmissions in elderly patients. Annals of Internal Medicine, 2009, 151, JC3.	3.9	2
32	Review: Â-blockers for hypertension increase risk of new onset diabetes. Evidence-Based Medicine, 2008, 13, 50-50.	0.6	14
33	Review: \hat{l}^2 -blockers for hypertension increase risk for new-onset diabetes compared with nondiuretic antihypertensive agents. ACP Journal Club, 2008, 148, 38.	0.1	1
34	Review: beta-blockers for hypertension increase risk for new-onset diabetes compared with nondiuretic antihypertensive agents. ACP Journal Club, 2008, 148, 38.	0.1	0
35	Discriminating Inhalational Anthrax From Community-Acquired Pneumonia Using Chest Radiograph Findings and a Clinical Algorithm. Chest, 2007, 131, 489-496.	0.8	30
36	Evaluation of Serious Adverse Drug Reactions. Archives of Internal Medicine, 2007, 167, 1041.	3.8	43

#	Article	IF	CITATIONS
37	Inadvertent intrathecal administration of vincristine. Community Oncology, 2007, 4, 45-46.	0.2	9
38	Hypersensitivity Cases Associated With Drug-Eluting Coronary Stents. Journal of the American College of Cardiology, 2006, 47, 175-181.	2.8	567
39	Clinical features and correlates of gemcitabine-associated lung injury. Cancer, 2006, 106, 2051-2057.	4.1	59
40	Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood, 2005, 106, 3343-3347.	1.4	101
41	The Research on Adverse Drug Events and Reports (RADAR) Project. JAMA - Journal of the American Medical Association, 2005, 293, 2131.	7.4	111
42	2005 Update on Accelerated FDA Approval of Drugs Used To Treat Hematologic Malignancies from the Research on Adverse Drug-Events and Reports (RADAR): Rate of Regular Approval Conversion Remains Low Blood, 2005, 106, 289-289.	1.4	1
43	Pure Red-Cell Aplasia and Epoetin Therapy. New England Journal of Medicine, 2004, 351, 1403-1408.	27.0	398
44	Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by Non???HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 120-125.	2.1	114
45	Accelerated FDA Approval of Drugs Used To Treat Hematologic Malignancies: Are Policy Changes Needed? Blood, 2004, 104, 266-266.	1.4	5
46	Severe Gemcitabine-Associated Lung Injury in Hodgkins Disease & Disease & Reporting Quality and Clinical Characteristics of Cases Reported in the Medical Literature and to the FDA Blood, 2004, 104, 3145-3145.	1.4	1
47	Long-Term Follow-Up of Recombinant Human Erythropoietin (epoetin)Induced Pure Red Cell Aplasia (PRCA): A Comparison of Data Collected through Active and Passive Pharmacovigilance Efforts Blood, 2004, 104, 5319-5319.	1.4	1
48	Subacute Thrombotic Events Associated with Drug Eluting Cardiac Stents May Be Localized Hypersensitivity Reactions to Polymers Blood, 2004, 104, 2198-2198.	1.4	0
49	Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program Blood, 2004, 104, 5320-5320.	1.4	0
50	Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project. Journal of Clinical Oncology, 2003, 21, 3859-3866.	1.6	62
51	Adverse drug events in emergency department patients. Annals of Emergency Medicine, 2002, 39, 258-267.	0.6	153
52	Pharmaceutical Care of Postoperative Nausea and Vomiting: Balanced Scorecard for Outcomes. Pharmacotherapy, 2000, 20, 1365-1374.	2.6	9
53	Particle Concentration Fluorescence Immunoassay of Gentamicin. Therapeutic Drug Monitoring, 1991, 13, 260-262.	2.0	4
54	Acute tolerance to cocaine in humans. Clinical Pharmacology and Therapeutics, 1988, 44, 1-8.	4.7	113

#	Article	IF	CITATION
55	Urinary Excretion of Cocaine, Benzoylecgonine, and Ecgonine Methyl Ester in Humans. Journal of Analytical Toxicology, 1988, 12, 301-306.	2.8	114
56	Pharmacokinetic Studies of Highly Purified Human Prolactin in Normal Human Subjects*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 299-304.	3.6	12
57	Effects of changing salt and water balance on renal kallikrein, kininogen and kinin. Kidney International, 1987, 31, 836-841.	5.2	7
58	Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clinical Pharmacology and Therapeutics, 1987, 42, 107-112.	4.7	30